Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December 31, 2025.
Q4 2025 earnings call recap: revenue +19%, Decipher/Afirma volume growth, 2026 guidance and margin outlook plus launch catalysts—read now.
Brown Capital Management, an investment management company, released its fourth quarter 2025 investor letter for “The Brown Capital Management Small Company Fund”. A copy of the letter can be ...
Leveraged the GRID research platform to drive clinical evidence, with the majority of 2025 Afirma publications being GRID-related. Executed a strategic restructuring of Veracyte SAS to improve ...
SOUTH SAN FRANCISCO, Calif. (AP) — Veracyte Inc. (VCYT) on Wednesday reported fourth-quarter profit of $41.1 million.
Veracyte VCYT has consistently gained from the strength of its Afirma and Decipher tests. With Decipher expanding into metastatic and localized disease areas, the growth is likely to continue in the ...
Zacks.com on MSN
Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally?
Veracyte VCYT shares have surged 45.6% in the past year, showing impressive momentum. It has significantly outperformed the ...
Veracyte VCYT has seen impressive growth over the past year, with its shares jumping 44%. It has significantly outperformed the industry’s 3.9% rise and the S&P 500 composite’s 24.4% gain. With a ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and ...
Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. Replays ...
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data for a molecular signature to predict hormone therapy benefit in men ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results